Pathology Analysis & Statistics, July 2014

Talk to Louis

+1 718 618 4302

Search inside this page

Publishers

  • All
    • Global Data

All regions

You might be interested in: cancer, breast cancer, prostate cancer, more »

1-30 of about 2 100 reports

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

  • $ 6 495
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...

  • Industries : Pathology
  • Countries : World, France, China, Italy, Japan, Brazil, Germany, India, Spain, United Kingdom, United States, Europe
OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

  • $ 5 995
  • Industry report
  • July 2014
  • by Global Data

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of ...

  • Industries : Pathology
OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 5 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

  • Industries : Pathology
OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018

  • $ 5 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018 Summary Amyotrophic lateral sclerosis (ALS) is a rare, but fatal, motor neuron disease (MND) characterized ...

  • Industries : Pathology
  • Countries : World, United States, Japan
PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market ...

  • Industries : Pathology
  • Countries : Australia
MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts

  • $ 4 450
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose ...

  • Industries : Pathology
  • Countries : South America, Brazil, World
MediPoint: Companion Diagnostic Tests in Oncology - APAC Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - APAC Analysis and Market Forecasts

  • $ 4 450
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - APAC Analysis and Market Forecasts Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...

  • Industries : Pathology
  • Countries : China, Japan, India
MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts

  • $ 4 450
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...

  • Industries : Pathology
  • Countries : United States
MediPoint: Companion Diagnostic Tests in Oncology - EU Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - EU Analysis and Market Forecasts

  • $ 4 450
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - EU Analysis and Market Forecasts Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...

  • Industries : Pathology
  • Countries : France, Italy, Germany, Spain, United Kingdom, Europe
EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • July 2014
  • by Global Data

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

  • Industries : Pathology
  • Countries : Germany, World, United States, Spain, United Kingdom, Italy, France, Japan
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • May 2014
  • by Global Data

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023 Summary Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are ...

  • Industries : Pathology
EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2023

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • May 2014
  • by Global Data

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2023 Summary Non-Hodgkin's lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body's immune ...

  • Industries : Pathology
  • Countries : United States, Germany, World, United Kingdom, Spain, Italy, France
EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • May 2014
  • by Global Data

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023 Summary Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood ...

  • Industries : Pathology
  • Countries : United States, France, World, Spain, Italy, Germany
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players

MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players

  • $ 3 500
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe ...

  • Industries : Pathology
Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia
Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom, Oceania
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : United States, Australia, World
Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, United States, Spain, Italy, France, Germany, United Kingdom, Europe, Oceania
Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe, Oceania
About 38 000 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description

  • Media Release
  • July 2014
    13 pages
  • Pathology  

    Cancer  

  • Europe  

    United States  

    Switzerland  

View report >

35 Companies

Read our Company Profiles

Eli Lilly and Co.

United States

Pfizer Inc.

United States

AstraZeneca PLC

United Kingdom

Lilly and Co.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.